ISOLATION AND CHARACTERIZATION OF A METASTATIC EB-LIKE TUMOR VARIANT HIGHLY RESPONSIVE TO INTERLEUKIN (IL)-2 AND TO COMBINATION CYTOKINE THERAPY WITH IL-2 IL-1-BETA AND IL-1-BETA/INTERFERON-ALPHA/BETA/

Citation
L. Gabriele et al., ISOLATION AND CHARACTERIZATION OF A METASTATIC EB-LIKE TUMOR VARIANT HIGHLY RESPONSIVE TO INTERLEUKIN (IL)-2 AND TO COMBINATION CYTOKINE THERAPY WITH IL-2 IL-1-BETA AND IL-1-BETA/INTERFERON-ALPHA/BETA/, Invasion & metastasis, 13(3), 1993, pp. 147-162
Citations number
39
Categorie Soggetti
Oncology
Journal title
ISSN journal
02511789
Volume
13
Issue
3
Year of publication
1993
Pages
147 - 162
Database
ISI
SICI code
0251-1789(1993)13:3<147:IACOAM>2.0.ZU;2-L
Abstract
In this study, we describe the origin and characterization of a new me tastatic tumor cell line (p11-R-Eb) obtained after i.p. passages of th e nonmetastatic Eb lymphoma cells into DBA/2 mice. The p11-R-Eb cells exhibited the same morphology and in vitro growth properties and chrom osome markers as the original Eb cells. FACS analysis of the p11-R-Eb cells also revealed a close similarity to the Eb cells. Moreover, the p11-R-Eb cells were specifically killed by anti-Eb cytotoxic lymphocyt es. In spite of all these characteristics of the Eb line, p11-R-Eb cel ls metastasized to the liver when injected i.v. or s.c. in DBA/2 mice. Peritumoral interleukin (IL)-2 treatment resulted in a potent antitum or response in DBA/2 mice transplanted s.c. with p11-R-Eb cells. In co ntrast, the same IL-2 regimen did not significantly increase the survi val time of mice transplanted with the highly metastatic ESb cell line . Combined IL-1/IL-2 treatments of established p11-R-Eb tumors resulte d in a synergistic antitumor effect and in tumor regression in 70% of the injected mice. Similarly, combined peritumoral treatment with IL-1 and interferon-alpha/beta, which were poorly effective or ineffective as single cytokine therapy, resulted in a marked antitumor effect, an d 30% of the mice were cured. Spleen cells from IL-1/IL-2-treated p11- R-Eb-cell-injected mice showed a marked antitumor activity when assaye d in a Winn assay with homologous tumor cells. This antitumor activity was eliminated by preincubation of spleen cells with antibodies to CD 4 and complement and markedly inhibited by anti-asialo GM(1) antibodie s. P11-R-Eb cells represent, therefore, a new tumor model which may be useful for investigating the relevant mechanisms which need to be act ivated to achieve a potent antitumor response to cytokine therapy in t he DBA/2 mouse host.